Ben-Sasson Shmuel Projects

Results Found (6)
Technology NameBriefcaseLead Researcher
Mechanism-Based Anti-Angiogenic Drug-Combination to Treat Cancer Tiltan Pharma is a start up company that developed a novel treatment for cancer which is now at  a phase-II clinical study in metastatic pancreatic cancer. The company has ...
More
Ben-Sasson Shmuel
  Our Innovation   Based on a provocative working hypothesis, we most probably identified the molecular origin of insulin resistance (IR). Systemic IR is induced via post-translational modification (PTM) of liver key regulatory proteins. We ...
More
Ben-Sasson Shmuel
 About the company Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into thermogenic, brown-like adipose ...
More
Ben-Sasson Shmuel
Background Cancer cells lose their epigenetic checks and balances followed by unscheduled shut-off of tumor-suppressor genes and switch-on of genes that promote cell proliferation. 1st generation of anti-cancer epigenetic drugs are ...
More
Ben-Sasson Shmuel
  Category LifeSciences and BioTechnology    Keywords Pain, Opioid receptor, Addiction, Opioid addiction, Narcotics, AnalgesiaApplication Severe, high-impact chronic pain affects 20 million people in the US annually, and presents a common, ...
More
Ben-Sasson Shmuel
  Background One of the largest families of receptors in the human genome is that of the 7 -ransmembrane receptor (7-TMR) superfamily, also known as G-protein coupled receptors (GPCRs), numbering approximately 2000. G-protein coupled receptors ...
More
Ben-Sasson Shmuel